Literature DB >> 21423788

Clinical trial structures.

Scott R Evans1.   

Abstract

Most errors in clinical trials are a result of poor planning. Fancy statistical methods cannot rescue design flaws. Thus careful planning with clear foresight is crucial. The selection of a clinical trial design structure requires logic and creativity. Common structural designs are discussed.

Entities:  

Year:  2010        PMID： 21423788      PMCID： PMC3059315          DOI： 10.6030/1939-067x-3.1.8

Source DB:  PubMed          Journal:  J Exp Stroke Transl Med        ISSN： 1939-067X


  8 in total

1.  Claims of equivalence in medical research: are they supported by the evidence?

Authors:  W L Greene; J Concato; A R Feinstein
Journal:  Ann Intern Med       Date:  2000-05-02       Impact factor: 25.391

2.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.

Authors:  Gilda Piaggio; Diana R Elbourne; Douglas G Altman; Stuart J Pocock; Stephen J W Evans
Journal:  JAMA       Date:  2006-03-08       Impact factor: 56.272

3.  Use of ramipril in preventing stroke: double blind randomised trial.

Authors:  Jackie Bosch; Salim Yusuf; Janice Pogue; Peter Sleight; Eva Lonn; Badrudin Rangoonwala; Richard Davies; Jan Ostergren; Jeff Probstfield
Journal:  BMJ       Date:  2002-03-23

4.  Predicted Interval Plots (PIPS): A Graphical Tool for Data Monitoring of Clinical Trials.

Authors:  Lingling Li; Scott R Evans; Hajime Uno; L J Wei
Journal:  Stat Biopharm Res       Date:  2009-11-01       Impact factor: 1.452

5.  Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  J C Shlay; K Chaloner; M B Max; B Flaws; P Reichelderfer; D Wentworth; S Hillman; B Brizz; D L Cohn
Journal:  JAMA       Date:  1998-11-11       Impact factor: 56.272

6.  Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study.

Authors:  Scott R Evans; Susan E Krown; Marcia A Testa; Timothy P Cooley; Jamie H Von Roenn
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

7.  Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.

Authors:  M J Brodie; E Perucca; P Ryvlin; E Ben-Menachem; H-J Meencke
Journal:  Neurology       Date:  2007-02-06       Impact factor: 9.910

8.  A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain.

Authors:  Scott R Evans; David M Simpson; Douglas W Kitch; Agnes King; David B Clifford; Bruce A Cohen; Justin C McArthur
Journal:  PLoS One       Date:  2007-07-25       Impact factor: 3.240
  8 in total
  42 in total

1.  Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study.

Authors:  Christian Hoppe; Patrick Obermeier; Susann Muehlhans; Maren Alchikh; Lea Seeber; Franziska Tief; Katharina Karsch; Xi Chen; Sindy Boettcher; Sabine Diedrich; Tim Conrad; Bron Kisler; Barbara Rath
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

2.  Chronic antioxidant administration restores macrovascular function in patients with heart failure with reduced ejection fraction.

Authors:  Kanokwan Bunsawat; Stephen M Ratchford; Jeremy K Alpenglow; Soung Hun Park; Catherine L Jarrett; Josef Stehlik; Stavros G Drakos; Russell S Richardson; D Walter Wray
Journal:  Exp Physiol       Date:  2020-06-18       Impact factor: 2.969

3.  Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Semin Neurol       Date:  2020-09-09       Impact factor: 3.420

4.  Use of placebos in Phase 1 preventive HIV vaccine clinical trials.

Authors:  Yunda Huang; Shelly T Karuna; Holly Janes; Nicole Frahm; Martha Nason; Paul T Edlefsen; James G Kublin; Lawrence Corey; M Juliana McElrath; Peter B Gilbert
Journal:  Vaccine       Date:  2014-10-23       Impact factor: 3.641

Review 5.  Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Matt Stevenson; Abdullah Pandor; Jean Hamilton; John Stevens; Clare Rowntree; Marrissa Martyn-St James; Andrew Rawdin; Ruth Wong
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

6. 

Authors:  Mansoureh Ashghali Farahani; Samira Soleimanpour; Samantha J Mayo; Jamie S Myers; Prabdeep Panesar; Farzaneh Ameri
Journal:  Can Oncol Nurs J       Date:  2022-02-01

Review 7.  Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Abdullah Pandor; Matt Stevenson; John Stevens; Marrissa Martyn-St James; Jean Hamilton; Jenny Byrne; Claudius Rudin; Andrew Rawdin; Ruth Wong
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

Review 8.  Improving vaccine efficacy against malignant glioma.

Authors:  Erik Ladomersky; Matthew Genet; Lijie Zhai; Galina Gritsina; Kristen L Lauing; Rishi R Lulla; Jason Fangusaro; Alicia Lenzen; Priya Kumthekar; Jeffrey J Raizer; David C Binder; C David James; Derek A Wainwright
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

9.  The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder.

Authors:  Swe Zin Aye; Han Ni; Htwe H Sein; San T Mon; Qishi Zheng; Yoko Kin Yoke Wong
Journal:  Cochrane Database Syst Rev       Date:  2021-02-14

10.  Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction.

Authors:  Kanokwan Bunsawat; Stephen M Ratchford; Jeremy K Alpenglow; Soung Hun Park; Catherine L Jarrett; Josef Stehlik; Adam S Smith; Russell S Richardson; D Walter Wray
Journal:  J Appl Physiol (1985)       Date:  2020-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.